DBV Technologies SA (DBV) verðbréfaverð og fréttir – Google Finance

Fjármál

HeimDBV • EPA

DBV Technologies SA

2,77 €

20. okt., 16:17:48 GMT+2 · EUR · EPA · Lagalegir fyrirvarar

Invesco DB Agriculture Fund

26,70 $

DBA0,60%

Invesco DB US Dollar Index Bearish Fund

18,66 $

UDN0,11%

Invesco DB US Dollar Index Bullish Fund

27,78 $

UUP0,11%

Invesco DB Precious Metals Fund

99,08 $

DBP1,93%

Invesco DB Commodity Index Tracking Fund

22,19 $

DBC0,29%

DB Energy SA

11,60 zł

DBE2,52%

Invesco DB Oil Fund

12,25 $

DBO1,29%

Invesco DB Base Metals Fund

21,08 $

DBB0,62%

Cellectis SA

3,27 €

ALCLS4,25%

Nanobiotix SA

21,50 €

NANO3,59%

HlutabréfSkráð hlutabréf í FR

Við síðustu lokun

2,92 €

Dagbil

2,68 € - 2,94 €

Árabil

0,51 € - 3,18 €

Markaðsvirði

412,66 m. EUR

Meðalmagn

1,07 m.

V/H-hlutf.

-

A/V-hlutfall

-

Aðalkauphöll

EPA

Viðskiptafréttir

fyrir 38 mínútum

TSX Benefits From Easing US-China Tensions

fyrir 59 mínútum

TSX opens higher on mining boost; inflation data, earnings in focus

fyrir 1 klukkustund

TSX Today: What to Watch for in Stocks on Monday, October 20

The Globe and Mail

fyrir 2 klukkustundum

The most oversold and overbought stocks on the TSX

Investing News Network

fyrir 3 klukkustundum

1911 GOLD PROVIDES UPDATE ON "BEST EFFORTS" LIFE OFFERING AND PRIVATE PLACEMENT

Investing.com Canada

fyrir 3 klukkustundum

TSX futures point higher with U.S.-China trade discussions in focus

Um

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia

Stofnsett

29. mar. 2002

Vefsvæði

dbv-technologies.com

Starfsfólk

109

Leit

Hreinsa leit

Loka leit

Google forrit

Aðalvalmynd